학술논문
Maintenance of response in moderate‐to‐severe psoriasis after withdrawal of the interleukin (IL)‐17A and IL‐17F nanobody sonelokimab: is there a role for IL‐17F in disease reoccurrence?
Document Type
Article
Author
Source
Subject
*PSORIASIS
*TERMINATION of treatment
*
Language
ISSN
0007-0963